Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2018, Article ID 8408015, 3 pages
https://doi.org/10.1155/2018/8408015
Case Report

Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy

1Department of Internal Medicine, Northwell Health Staten Island University Hospital, Staten Island, NY, USA
2Department of Hematology and Oncology, Northwell Health Staten Island University Hospital, Staten Island, NY, USA
3Department of Nephrology, Northwell Health Staten Island University Hospital, Staten Island, NY, USA

Correspondence should be addressed to Sandy El Bitar; moc.liamg@78ratibydnas

Received 26 October 2017; Accepted 18 January 2018; Published 31 January 2018

Academic Editor: Raffaele Palmirotta

Copyright © 2018 Sandy El Bitar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer,” New England Journal of Medicine, vol. 366, no. 26, pp. 2443–2454, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Borghaei, L. Paz-Ares, L. Horn et al., “Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer,” New England Journal of Medicine, vol. 373, no. 17, pp. 1627–1639, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. N. A. Rizvi, J. Mazieres, D. Planchard et al., “Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial,” Lancet Oncology, vol. 16, no. 3, pp. 257–265, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Jung, X. Zeng, and M. Bilusic, “Nivolumab-associated acute glomerulonephritis: a case report and literature review,” BMC Nephrology, vol. 17, no. 1, p. 188, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Murakami, T. J. Borges, M. Yamashita, and L. V. Riella, “Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma,” Clinical Kidney Journal, vol. 9, no. 3, pp. 411–417, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. J. W. Vandiver, Z. Singer, and C. Harshberger, “Severe hyponatremia and immune nephritis following an initial infusion of nivolumab,” Targeted Oncology, vol. 11, no. 4, pp. 553–556, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Bickel, I. Koneth, A. Enzler-Tschudy, J. Neuweiler, L. Flatz, and M. Fruh, “Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma,” BMC Cancer, vol. 16, no. 1, p. 656, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Ribas, “Tumor immunotherapy directed at PD-1,” New England Journal of Medicine, vol. 366, no. 26, pp. 2517–2519, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. N. M. La-Beck, G. W. Jean, C. Huynh, S. K. Alzghari, and D. B. Lowe, “Immune checkpoint inhibitors: new insights and current place in cancer therapy,” Pharmacotherapy, vol. 35, no. 10, pp. 963–976, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Hofmann, A. Forschner, C. Loquai et al., “Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy,” European Journal of Cancer, vol. 60, pp. 190–209, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. E. P. Cohen, B. Bastani, M. R. Cohen, S. Kolner, P. Hemken, and S. L. Gluck, “Absence of H(+)-ATPase in cortical collecting tubules of a patient with Sjogren’s syndrome and distal renal tubular acidosis,” Journal of American Society of Nephrology, vol. 3, no. 2, pp. 264–271, 1992. View at Google Scholar